paper_id,claim,figure_id,title,caption,local_image_path,url
PMC6967289,Patients who provided written informed consent entered a screening period of up to 28 days to establish study criteria (visit 1) (Fig. 1).,PMC6967289_figure_1,Fig. 1.,Study design,./data/PMC6967289/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbc/6967289/92cb53e91e55/41030_2019_96_Fig1_HTML.jpg
PMC6967289,"Log-transformed biomarker data were evaluated by a linear mixed-effects model, with visit variable as a fixed effect and patient as a random effect to determine whether on-study biomarker levels at weeks 4, 12, and 24 differed from baseline, with two-sided 95% confidence intervals.Results
Patient Disposition
A total of 31 patients with IPF receiving background pirfenidone were screened, of whom 10 were deemed ineligible (Fig. 2).",PMC6967289_figure_2,Fig. 2.,"Patient disposition. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, HRCT high-resolution computed tomography, IPF idiopathic pulmonary fibrosis",./data/PMC6967289/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbc/6967289/4747c7cb2c56/41030_2019_96_Fig2_HTML.jpg
PMC6967289,"No meaningful change from baseline was observed at weeks 4, 12, and 24 after vismodegib treatment (Fig. 3).",PMC6967289_figure_3,Fig. 3.,Individual CXCL14 levels. Plasma CXCL14 levels in individuals over time after initiation of vismodegib treatment. Baseline is the patient’s last observation prior to initiation of vismodegib. Dashed lines connect matched longitudinal samples from individual patients. CXCL14 C-X-C motif chemokine ligand 14,./data/PMC6967289/images/figure_3.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbc/6967289/aec1c35ba10a/41030_2019_96_Fig3_HTML.jpg
PMC6967289,"Results
Patient Disposition
A total of 31 patients with IPF receiving background pirfenidone were screened, of whom 10 were deemed ineligible (Fig. 2).",PMC6967289_figure_2,Fig. 2.,"Patient disposition. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, HRCT high-resolution computed tomography, IPF idiopathic pulmonary fibrosis",./data/PMC6967289/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbc/6967289/4747c7cb2c56/41030_2019_96_Fig2_HTML.jpg
PMC6967289,"Patient Disposition
A total of 31 patients with IPF receiving background pirfenidone were screened, of whom 10 were deemed ineligible (Fig. 2).",PMC6967289_figure_2,Fig. 2.,"Patient disposition. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, HRCT high-resolution computed tomography, IPF idiopathic pulmonary fibrosis",./data/PMC6967289/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbc/6967289/4747c7cb2c56/41030_2019_96_Fig2_HTML.jpg
PMC6967289,"A total of 31 patients with IPF receiving background pirfenidone were screened, of whom 10 were deemed ineligible (Fig. 2).",PMC6967289_figure_2,Fig. 2.,"Patient disposition. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, HRCT high-resolution computed tomography, IPF idiopathic pulmonary fibrosis",./data/PMC6967289/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edbc/6967289/4747c7cb2c56/41030_2019_96_Fig2_HTML.jpg
